Celltrion Launches Remsima SC (biosimilar, infliximab) for the Treatment of Autoimmune Diseases in the Netherlands

 Celltrion Launches Remsima SC (biosimilar, infliximab) for the Treatment of Autoimmune Diseases in the Netherlands

Celltrion Initiates P-I Study of its COVID-19 Antibody Treatment in South Korea

  • The company has launched the Remsima SC, a biosimilar referencing Janssen’s Remicade (infliximab) on Apr 27, 2020. The clinical study demonstrated Remsima SC has similar results in efficacy and safety compared to the IV formulation
  • The launch followed market releases of the product in Germany and the UK in Feb and Mar’2020 respectively. Before the launch in the Netherlands, the company had an online symposium, attended by 200 medical professionals on Apr 21, 2020
  • Celltrion collaborated with CZ to reimburse the entire treatment fee for Remsima SC and allows patients to administer it directly at home. Additionally, CZ’s SC formulation is more expensive than IV formulation, but ‘Remsima SC’ is expected to be a good alternative to the infliximab formulation

Click here ­to­ read full press release/ article | Ref: Celltrion | Image: Celltrion

Related News: Celltrion’s Remsima SC (biosimilar, infliximab) Receives KFDA’s Approval for Rheumatoid Arthritis

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post